Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxytocin morpholino antisense is an antisense morpholino oligonucleotide designed to selectively inhibit the translation of oxytocin (Oxt) mRNA. Developed primarily as a research tool by researchers at the University of California, Davis, this synthetic oligonucleotide blocks the synthesis of the neuropeptide oxytocin in specific brain regions, such as the paraventricular nucleus (PVN) and the bed nucleus of the stria terminalis (BNST). In preclinical animal models, particularly California mice (*Peromyscus californicus*), localized administration of this morpholino has been utilized to study the distinct roles of specific oxytocin-producing neuronal populations in modulating social behaviors, including social approach, social avoidance, and social vigilance under stress or unstressed conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxytocin morpholino antisense.